Oxcarbazepine (OXC) is indicated for treating partial-onset and generalized tonic-clonic seizures, in both adults and children aged over 6 years, as monotherapy or adjuvant therapy. Trials data and extensive clinical experience demonstrate generally good tolerability and antiepileptic efficacy similar to carbamazepine (CBZ), sodium valproate or phenytoin. Since the UK launch of OXC in March 2000, UK collaborators have pooled experience to optimize prescribing recommendations for adults. Many patients are successfully managed using the prescribing information recommended titration schedule. However, evolving clinical experience suggests a slower introduction is preferable (e.g. 150 mg day one, then 300 mg daily, increased by 300 mg weekly) both for monotherapy and adjuvant therapy. Overnight 'switch' from CBZ to OXC (using CBZ:OXC ratio of 1:1.5) has been used for patients responsive to CBZ, but with dose-related side-effects. Owing to individual variations in CBZ enzyme autoinduction, however, overnight switching is advised only for those on CBZ<800 mg daily; otherwise, slower switching is recommended. OXC is not the first choice alternative for patients developing a CBZ rash owing to increased OXC rash rate in CBZ sensitive subjects. Hyponatraemia may be more common (albeit often asymptomatic) than trials data suggest, especially in the elderly. Serum sodium monitoring is unnecessary, however, unless relevant risk factors or pointers exist. Severe haematological dyscrasias have not been reported with OXC. The enzyme inducing interaction of OXC with ethinyloestradiol and levonorgestrel necessitates additional precautions for women using hormonal contraception.
INTRODUCTION
The challenge of epilepsy management An estimated 50 million people worldwide suffer from epilepsy. With an ageing population, more people surviving serious head trauma, and stroke, the number of people experiencing seizures is increasing. Partial seizures are the most common type, occurring in about 60% of all patients with epilepsy. Up to 30% of all patients with epilepsy will not achieve adequate seizure control and their lives are blighted by adverse events as a result of drug therapy as well as seizures. The impetus to develop new drugs to treat epilepsy is driven by the need for new AEDs that are at least as effective as existing therapies, but are better tolerated.
Oxcarbazepine
Oxcarbazepine (Trileptal) was launched in the UK in March 2000. At launch, oxcarbazepine was indicated for use as monotherapy and adjunctive therapy for patients with partial seizures with or without sec-ondary generalized tonic-clonic seizures. Clinical experience worldwide is already extensive and spans more than 250 000 patient years. This compares with the consideration that 100 000 patient years of experience is sufficient to determine idiosyncratic adverse events 1 .
The clinical trials programme for oxcarbazepine was extensive. It has been evaluated against placebo as well as in head-to-head comparative trials with three AEDs traditionally considered as first-choice agents (carbamazepine [CBZ], valproate and phenytoin) where it demonstrated comparable efficacy [2] [3] [4] . In monotherapy comparative trials seizure freedom was achieved in 52%, 57% and 59% of patients receiving oxcarbazepine vs. CBZ, valproate or phenytoin [2] [3] [4] . Oxcarbazepine was significantly better tolerated than CBZ (P = 0.04) and phenytoin (P = 0.02), according to the discontinuation rates due to adverse events.
Oxcarbazepine has also been shown to be effective in adjunctive trials, one in adults and one in children, where it demonstrated dose-dependent efficacy when added to drug regimens of at least two AEDs 5, 6 . Oxcarbazepine demonstrated a dose-dependent effect on seizure control with a reduction in seizure frequency from baseline at 600, 1200 and 2400 mg per day of 26%, 40% and 50%, respectively 5 . In add-on therapy, seizure freedom could be achieved in a dosedependent manner so that at 600 mg per day 3% of patients were seizure free, rising to 22% of patients becoming seizure free at the top dose of oxcarbazepine of 2400 mg per day 5 .
Dosing
Currently, when used as monotherapy it is recommended that oxcarbazepine should be initiated at a dose of 600 mg per day administered twice daily as a divided dose. If clinically required, the dose of oxcarbazepine can be increased at weekly intervals by 600 mg per day until seizure control is achieved up to a maximum dose of 2400 mg per day. Generally, a therapeutic response is observed at 1200 mg per day in previously treatment naive patients (900-1200 mg per day is a usual target dose) and at 2400 mg per day for patients with refractory seizures where previous monotherapy has failed 7 . If rapid seizure control is required, the dose of oxcarbazepine can be increased rapidly to 2400 mg per day over 48 hours in a controlled hospital setting 8 .
Similarly, when oxcarbazepine is prescribed as adjunctive therapy in adults it is recommended that treatment is initiated at 600 mg per day and titrated at weekly intervals by 600 mg per day. In a clinical trial of oxcarbazepine as add-on therapy it was shown to have a dose-dependent effect on seizure control with up to 22% of patients achieving seizure freedom 5 .
CURRENT CLINICAL EXPERIENCE
Current clinical experience has shown that if oxcarbazepine therapy is initiated and titrated as per the prescribing information (PI) 9 , some patients have an excellent response whilst others have a less positive outcome. For some patients, initiation of oxcarbazepine at 600 mg per day and titration on a weekly basis of 600 mg per day is well tolerated and effective. But for other patients, this dosing and titration schedule has proved unsuccessful with instances of poor tolerability for both monotherapy and adjunctive therapy.
Evolving clinical experience is demonstrating that a 'go low, go slow' approach would be more appropriate for some patients. The dosing schedule recommended in the PI has been derived from clinical trials experience where strict exclusion and inclusion criteria operate, for this reason actual clinical experience can differ markedly for some patients, whilst for others the recommended dosing schedule from the PI remains more appropriate.
A meeting of the UK oxcarbazepine advisory panel of epileptologists was convened with a view to establishing best clinical practice for adults. From this a consensus opinion could be disseminated to all specialists to improve clinical practice with oxcarbazepine and ultimately patient care. The recommendations for the use of oxcarbazepine in children remain unchanged from the PI.
CLINICAL RECOMMENDATIONS FOR OXCARBAZEPINE Monotherapy
• It was recommended that oxcarbazepine could be used effectively as first-line monotherapy in treatment naive patients.
• To improve patient outcome it was recommended that for most patients oxcarbazepine monotherapy could be initiated at 300 mg per day and titrated at weekly intervals by 300 mg per day.
• It was recommended that treatment with oxcarbazepine be initiated in the following way: a first dose of oxcarbazepine 150 mg be administered to patients at bedtime on day 1 and then treatment continued at 300 mg per day from day 2 (administered as a divided dose).
• Using this schedule, the incidence of rash is likely to be reduced and tolerability improved. Therapeutic doses (900-1200 mg per day) are still reached quickly (within 2-3 weeks).
• Rapid initiation-titration with oxcarbazepine can be undertaken if clinically needed, but this should be considered only for very close supervision within a ward setting.
Adjunctive therapy
• It is recommended that when oxcarbazepine is added to a drug regimen it should ideally eventually substitute for one of the existing drugs.
• As in monotherapy, it was recommended that a 'go low, go slow' approach be adopted, and that the overall drug burden for an individual patient be considered. When deciding to initiate oxcarbazepine as add-on therapy in patients already receiving AEDs, clinicians need to consider carefully the overall drug burden for the patient, as tolerability in these patient groups is mainly dependent on the concomitant drug load. Hence it may be prudent to reduce the dose of concomitant AED therapy prior to and during initiation of oxcarbazepine. If oxcarbazepine is replacing one or more of the AED therapies (e.g. CBZ), the panel felt that clinicians should be aware of potential increases in the total drug load-due to the lack of autoinduction of oxcarbazepine.
• It was recommended that oxcarbazepine should be considered as adjunctive therapy firstly for patients not receiving carbamazepine and secondly for patients receiving carbamazepine <800 mg per day.
• For patients receiving carbamazepine as part of their drug regimen the dose of oxcarbazepine should be introduced cautiously and the dose of carbamazepine reduced to below the maximum tolerated dose of CBZ (i.e. <800 mg per day), in order to circumvent tolerability issues.
• For patients on high doses of concomitant AEDs it was recommended that oxcarbazepine should be added into the regimen more slowly than recommended in the PI, and that the initiation dose of oxcarbazepine be considered in light of the patient's overall drug burden. It has been suggested that for patients receiving 2-3 AEDs initiation may need to be very slow with an initiation dose of 150 mg per day, whilst those receiving 1-2 AEDs oxcarbazepine might be initiated faster at a dose of 300 mg per day.
Switch therapy
• Where possible substitution therapy is preferable to add-on therapy to circumvent increasing a patient's overall drug burden.
• It is recommended that immediate ('overnight') switch should be considered only for patients receiving CBZ monotherapy (ideally, <800 mg per day), but who are intolerant of its side effects or are experiencing inadequate seizure control. For patients in other situations (particularly those receiving AED polytherapy) a gradual switch over 2-3 weeks is more appropriate: gradual conversion from CBZ to oxcarbazepine may be achieved by initiating oxcarbazepine as 150 mg b.i.d, and then titrating upwards by 150 mg every 2 days. This switch method is still rapid and ensures that patients achieve seizure control quickly. The CBZ should be reduced by 25% prior to the titration of oxcarbazepine, to avoid problems of increased drug load (due to lack of autoinduction by oxcarbazepine), which could potentially lead to increased tolerability issues.
• Rapid switching from CBZ to oxcarbazepine when the dose of CBZ is below 800 mg per day is thought not to be problematic. However, when a switch is undertaken in patients receiving more than 800 mg per day, clinical experience has shown that, in some cases, patients may experience increased side effects. This is thought to be due to the variable degree of CBZ autoinduction from patient to patient, which could result in the same plasma concentration of CBZ occurring in patients receiving 1 or 2 g per day, depending on the extent of autoinduction. Using equivalent doses of oxcarbazepine in this situation is clearly inappropriate.
• Commonly in the UK slow release carbamazepine is used (Tegretol Retard). When switching from newer formulations of CBZ (i.e. slow release) to oxcarbazepine, US experience has shown that a 1 : 1 or 1 : 1.2 switch is preferable due to differences in pharmacokinetics between slow release formulations of CBZ and conventional formulations of CBZ (compared with Danish experience of conventional CBZ: oxcarbazepine ratio 1 : 1.5) 9 .
• Importantly, if a patient has experienced a rash with carbamazepine before switch to oxcarbazepine, then oxcarbazepine therapy should ideally be initiated using the lower, slower initiationtitration schedule recommended here to prevent cross-sensitivity. This is, of course, dependent on individual patient circumstances and the balance of seizure control against side effects. Oxcarbazepine would not be the first choice therapy for switch medication for patients experiencing a previous rash with carbamazepine.
• Clinicians need to be aware that oxcarbazepine is not an autoinducing drug. Thus, it is possible that switching from an autoinducing drug (e.g. CBZ) in AED polytherapy to oxcarbazepine, can increase the plasma concentrations of the drugs remaining in the regimen-this may result in increased side effects, care should therefore be exercised in these patients to ensure a positive outcome.
Safety
• It is noted that the incidence of hyponatraemia appears to be dose dependent and that a slower, lower titration-initiation schedule such as that recommended here may help to prevent it.
• Clinical experience suggests that hyponatraemia (<125 mmol l −1 plasma sodium levels) may be commoner in clinical practice than seen in the clinical trials programme. However, most of these patients are asymptomatic, and hyponatraemia, if it occurs, tends to develop within the first 3 months of treatment, consistent with the clinical trials data.
• It is recommended that hyponatraemia be managed through water restriction, dose reduction and, if required, discontinuation. The panel recommend that clinicians question their patients about their fluid intake.
• Routine monitoring for lowered plasma sodium is not necessary, except for patients receiving concomitant sodium depleting drugs (e.g. diuretics) or those with sodium-depleting disease, and may be advisable in patients exhibiting related symptoms (blurred vision, oedema, headache, confusion and worsening seizures).
• However, it is recommended that clinicians use their discretion and monitor patients who they deem to be at risk. Hyponatraemia is more common in elderly patients and these patients should be considered to be at a higher risk.
• The overall tolerability of oxcarbazepine is good. Oxcarbazepine is not associated with severe blood dyscrasias, agranulocytosis or aplastic anaemia.
• It was recommended that all women of childbearing age receiving oxcarbazepine (which is enzyme inducing with oral contraceptives) should be carefully counselled about the impact of oxcarbazepine on the contraceptive pill, prescribed a pill containing 50 µg of oestrogen and use additional barrier methods of contraception until hormonal cover is established (e.g. lack of breakthrough bleeding).
• However, some authorities recommend that all women taking an enzyme-inducing AED and a combined oral contraceptive, even if they are receiving a higher oestrogen dose and have good cycle control, should also use a barrier method of contraception or a spermicide as well. Progesterone-only oral contraceptives (mini-pill) taken with an enzyme-inducing AED cannot be relied upon to have their usual contraceptive efficacy 10 .
CONCLUSIONS
Since launch, it is clear that oxcarbazepine has proved to be an effective and well tolerated treatment of epilepsy. Oxcarbazepine does have benefits for patients, it is an effective and well tolerated drug with no evidence of haematological toxicity. These recommendations from the panel will serve to improve clinical practice and benefit patients. For some patients, oxcarbazepine can be used successfully as recommended in the PI. For others, however, oxcarbazepine therapy would be most beneficial if initiated at a lower dose over a slower timeframe than originally recommended. For patients already receiving other AEDs, oxcarbazepine is most suitable as an alternative therapy, but can be used successfully as add-on therapy after consideration of the impact of the lack of autoinduction and overall drug burden for the patient.
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